CNR2 and non-small cell lung carcinoma: In non-small-cell lung cancer cell lines, treatment with agonists targeting CB1 and CB2, or specifically CB2, were demonstrated to induce apoptosis, and to attenuate chemotaxis, metastatic growth and development, metastatic proliferation, and angiogenesis [192].